Stock Track | United Therapeutics Plummets 6.85% in Pre-Market as Q4 Earnings Miss Estimates

Stock Track

Feb 26, 2025

United Therapeutics (UTHR) stock plummeted 6.85% in the pre-market trading session on Wednesday, following the company's fourth-quarter 2024 earnings report that missed analysts' estimates on profit despite strong revenue growth.

The biopharmaceutical company reported earnings of $6.19 per diluted share for the quarter ended December 31, 2024, missing the analyst consensus estimate of $6.27 by 1.28%. However, United Therapeutics posted revenue of $735.9 million, beating expectations of $734.7 million.

While the company's revenue grew by nearly 20% year-over-year, driven by strong sales of its lung disorder inhaled-drug Tyvaso, investors appeared disappointed with the earnings miss. According to analysts, the seasonal trends in Tyvaso sales were not as robust as expected during the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1111377268"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111377268\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111377268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111377268","market":"hk","top_or_hot":-1,"title":"Stock Track | United Therapeutics Plummets 6.85% in Pre-Market as Q4 Earnings Miss Estimates","media":"Stock Track","content":"<p>United Therapeutics (UTHR) stock plummeted 6.85% in the pre-market trading session on Wednesday, following the company's fourth-quarter 2024 earnings report that missed analysts' estimates on profit despite strong revenue growth.</p>\n\n<p>The biopharmaceutical company reported earnings of $6.19 per diluted share for the quarter ended December 31, 2024, missing the analyst consensus estimate of $6.27 by 1.28%. However, United Therapeutics posted revenue of $735.9 million, beating expectations of $734.7 million.</p>\n\n<p>While the company's revenue grew by nearly 20% year-over-year, driven by strong sales of its lung disorder inhaled-drug Tyvaso, investors appeared disappointed with the earnings miss. According to analysts, the seasonal trends in Tyvaso sales were not as robust as expected during the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | United Therapeutics Plummets 6.85% in Pre-Market as Q4 Earnings Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | United Therapeutics Plummets 6.85% in Pre-Market as Q4 Earnings Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>United Therapeutics (UTHR) stock plummeted 6.85% in the pre-market trading session on Wednesday, following the company's fourth-quarter 2024 earnings report that missed analysts' estimates on profit despite strong revenue growth.</p>\n\n<p>The biopharmaceutical company reported earnings of $6.19 per diluted share for the quarter ended December 31, 2024, missing the analyst consensus estimate of $6.27 by 1.28%. However, United Therapeutics posted revenue of $735.9 million, beating expectations of $734.7 million.</p>\n\n<p>While the company's revenue grew by nearly 20% year-over-year, driven by strong sales of its lung disorder inhaled-drug Tyvaso, investors appeared disappointed with the earnings miss. According to analysts, the seasonal trends in Tyvaso sales were not as robust as expected during the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"","article_id":"1111377268","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111377268","pubTimestamp":1740580841,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"United Therapeutics  stock plummeted 6.85% in the pre-market trading session on Wednesday, following the company's fourth-quarter 2024 earnings report that missed analysts' estimates on profit despite strong revenue growth.The biopharmaceutical company reported earnings of $6.19 per diluted share for the quarter ended December 31, 2024, missing the analyst consensus estimate of $6.27 by 1.28%. However, United Therapeutics posted revenue of $735.9 million, beating expectations of $734.7 million.W","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"由于第四季度盈利未达预期，United Therapeutics盘前暴跌6.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"United Therapeutics (UTHR) stock plummeted 6.85% in the pre-market trading session on Wednesday, following the company's fourth-quarter 2024 earnings report that missed analysts' estimates on profit despite strong revenue growth.\nThe biopharmaceutical company reported earnings of $6.19 per diluted share for the quarter ended December 31, 2024, missing the analyst consensus estimate of $6.27 by 1.28%. However, United Therapeutics posted revenue of $735.9 million, beating expectations of $734.7 million.\nWhile the company's revenue grew by nearly 20% year-over-year, driven by strong sales of its lung disorder inhaled-drug Tyvaso, investors appeared disappointed with the earnings miss. According to analysts, the seasonal trends in Tyvaso sales were not as robust as expected during the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}